Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
2015 · Blood · 692 citations
https://doi.org/10.1182/blood-2015-06-651125
B
Barbara Eichhorst
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
436
Papers
21.5K
Citations
62
h-index
184
i10-index
Barbara Eichhorst is an academic researcher from TH Köln - University of Applied Sciences. The author has contributed to research in topics: Chronic Lymphocytic Leukemia Research & Lymphoma Diagnosis and Treatment & Immunodeficiency and Autoimmune Disorders. The author has an h-index of 62, co-authored 371 publications.
ORCID: 0000-0001-9990-6918Papers by this author
worksChronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2020 · Annals of Oncology · 553 citations
https://doi.org/10.1016/j.annonc.2020.09.019
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
2021 · Leukemia · 94 citations
https://doi.org/10.1038/s41375-021-01450-8
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
2024 · The Lancet Oncology · 66 citations
https://doi.org/10.1016/s1470-2045(24)00196-7
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748
2023 · Leukemia · 56 citations
https://doi.org/10.1038/s41375-023-01962-5
Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab
2013 · Leukemia · 37 citations
https://doi.org/10.1038/leu.2013.190
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat